ZEN003694 + Nivolumab/Ipilimumab for Cancer
Trial Summary
What is the purpose of this trial?
This trial is testing a new drug combination to treat solid tumors, especially in patients whose cancer doesn't respond to usual treatments. The drugs work by blocking tumor growth and boosting the immune system to fight the cancer. The goal is to find the best dose and see if the treatment can shrink or stabilize the tumors.
Will I have to stop taking my current medications?
The trial does not specify if you must stop taking your current medications. However, you cannot take medications that are inhibitors or inducers of CYP3A4, or fluoxetine, as these can interact with the trial drugs. It's important to discuss your current medications with the trial team to ensure there are no interactions.
What data supports the effectiveness of the drug combination ZEN003694, Nivolumab, and Ipilimumab for cancer?
The combination of nivolumab (Opdivo) and ipilimumab (Yervoy) has shown long-term effectiveness in treating advanced non-small cell lung cancer (NSCLC), with better results than chemotherapy, according to the CheckMate 227 trial. This suggests that these drugs can be effective in treating certain types of cancer.12345
Is the combination of ZEN003694, Nivolumab, and Ipilimumab safe for humans?
The combination of Nivolumab and Ipilimumab has been associated with increased risk of immune-related side effects, such as heart problems and other toxicities, especially when used together. These side effects can occur within the first few weeks of treatment, and more studies are needed to fully understand their safety profile.678910
What makes the drug combination of ZEN003694, Nivolumab, and Ipilimumab unique for cancer treatment?
This drug combination is unique because it combines ZEN003694, a novel agent, with Nivolumab and Ipilimumab, which are immune checkpoint inhibitors that help the immune system recognize and attack cancer cells. This approach may offer a new way to enhance the body's immune response against cancer, potentially improving outcomes compared to traditional chemotherapy.2341112
Eligibility Criteria
Adults with advanced solid tumors that have not responded to standard treatments may join this trial. They should have a good performance status, adequate organ function, and measurable disease that can be biopsied. Excluded are those with certain allergies, uncontrolled illnesses, severe heart conditions, active infections like HIV or hepatitis, recent immunosuppressive treatment, prior therapy targeting immune checkpoints or pregnant/breastfeeding women.Inclusion Criteria
Exclusion Criteria
Trial Timeline
Screening
Participants are screened for eligibility to participate in the trial
Dose Escalation (Doublet Treatment)
Patients receive nivolumab IV and ZEN003694 PO daily. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Dose Escalation and Dose Expansion (Triplet Treatment)
Patients receive nivolumab IV, ipilimumab IV, and ZEN003694 PO daily for up to 4 cycles. Beginning cycle 5, treatment continues with nivolumab and ZEN003694 only.
Follow-up
Participants are monitored for safety and effectiveness after treatment completion.
Treatment Details
Interventions
- Ipilimumab (Checkpoint Inhibitor)
- Nivolumab (Checkpoint Inhibitor)
- ZEN003694 (BET Bromodomain Inhibitor)
Ipilimumab is already approved in United States, European Union for the following indications:
- Advanced melanoma
- Stage III unresectable melanoma
- Stage IV metastatic melanoma
- Advanced melanoma
- Stage III unresectable melanoma
- Stage IV metastatic melanoma